Express News | Dyne Therapeutics Announces New Clinical Data From Phase 1/2 Deliver Trial of Dyne-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts
Small U.S. Stocks Decrease; Dyne Therapeutics Takes Biggest Hit
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
Oppenheimer Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $55
Stifel Maintains Dyne Therapeutics(DYN.US) With Buy Rating
Vaxcyte PCVX Phase 1/2 Data; Dyne Therapeutics DYN Phase 1/2 DMD Results
